AlphaCrest Capital Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-8,807
Closed -$1.08M 313
2022
Q3
$1.08M Sell
8,807
-4,483
-34% -$590K 0.07% 553
2022
Q2
$1.77M Sell
13,290
-9,796
-42% -$1.33M 0.09% 386
2022
Q1
$3.16M Buy
23,086
+3,811
+20% +$531K 0.18% 117
2021
Q4
$3.33M Sell
19,275
-3,246
-14% -$494K 0.12% 191
2021
Q3
$3.27M Sell
22,521
-26,504
-54% -$3.88M 0.17% 138
2021
Q2
$6.47M Buy
49,025
+30,929
+171% +$4.05M 0.28% 63
2021
Q1
$2.32M Sell
18,096
-1,118
-6% -$138K 0.13% 212
2020
Q4
$2.29M Buy
19,214
+12,337
+179% +$1.5M 0.19% 123
2020
Q3
$787K Sell
6,877
-335
-5% -$39.6K 0.09% 357
2020
Q2
$822K Sell
7,212
-2,620
-27% -$278K 0.14% 200
2020
Q1
$790K Sell
9,832
-4,842
-33% -$501K 0.1% 372
2019
Q4
$1.57M Buy
14,674
+5,026
+52% +$524K 0.13% 172
2019
Q3
$1.03M Buy
9,648
+5,582
+137% +$573K 0.06% 556
2019
Q2
$414K Buy
+4,066
New +$391K 0.04% 765
2019
Q1
Sell
-2,850
Closed -$237K 844
2018
Q4
$237K Buy
+2,850
New +$267K 0.07% 544

Other funds holding DGX

AlphaCrest Capital Management's DGX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Quest Diagnostics (DGX) in Q4 2022, closing a stake of 8,807 shares — an estimated $1.08M sold.

AlphaCrest Capital Management first reported a position in DGX in Q4 2018 and held it in 15 quarters. The position peaked at $6.47M in Q2 2021. 880 funds tracked by Wall St. Rank hold DGX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Quest Diagnostics position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 8,807 Quest Diagnostics shares in Q4 2022, an estimated $1.08M.
  • AlphaCrest Capital Management first reported a position in Quest Diagnostics in Q4 2018 and held it in 15 quarters.
  • AlphaCrest Capital Management's Quest Diagnostics position peaked at $6.47M in Q2 2021.
  • 880 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.